PROCEPT BioRobotics Corporation PRCT Debt Instrument, Unamortized Discount (Premium), Net

Debt Instrument, Unamortized Discount (Premium), Net at other companies

MedtronicMDT

——

Revenue$83.1M+20.2%

Gross profit$53.9M+22.2%

Operating income-$32.6M-18.8%

Net income-$31.6M-27.9%

EPS (diluted)-$0.56-24.4%

Cash & equivalents$12.2M-96.2%

Total debt$78.0M-11.8%

Total equity$347.7M-10.7%

Total assets$487.1M-6.2%

Operating cash flow-$38.1M-125%

CapEx$2.9M+58.7%

Free cash flow-$41.0M-118%

Market cap$1.19B-22.5%

Enterprise value$1.25B—

P/S3.7×—

Gross margin64%+1.3pp

Operating margin-33.9%-3.8pp

Net margin-31.8%-3.4pp

FCF margin-25%-5.7pp

Return on equity-27.8%+0.2pp

Debt / equity0.2×0.0×

Current ratio6.7×-2.2×

Reported directly by PROCEPT BioRobotics Corporation in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet.

The official record: PROCEPT BioRobotics Corporation’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is PROCEPT BioRobotics Corporation's debt instrument, unamortized discount (premium), net?: PROCEPT BioRobotics Corporation (PRCT) reported debt instrument, unamortized discount (premium), net of $336K in Q1 2026.
How has PROCEPT BioRobotics Corporation's debt instrument, unamortized discount (premium), net changed year-over-year?: PROCEPT BioRobotics Corporation's debt instrument, unamortized discount (premium), net decreased by 33.1% year-over-year, from $502K to $336K.